Business Context and Reporting Period
This Form 8-K filing by Histogenics Corporation (trading symbol HSGX) reports a material event occurring on April 30, 2019, with the report filed on May 6, 2019. The company is an emerging growth company incorporated in Delaware. The filing details the termination of a material definitive agreement regarding its principal executive offices located at 830 Winter Street, Waltham, Massachusetts.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or total debt. The document focuses exclusively on the financial terms of a lease termination agreement.
- Termination Payment: $1,342,102.93 payable to the landlord.
- Waived Contribution: Approximately $57,000 (undisbursed contribution amount waived by the company).
- Contingent Payment: Up to $315,795, payable if the "Parent Cash Adjustment Amount" in the related Merger Agreement equals or exceeds 5.0%.
Material Changes Versus Prior Period
The primary material change is the acceleration of the lease expiration date for 25,472 rentable square feet. The original scheduled termination date was December 31, 2024, but the agreement terminates the lease effective April 30, 2019. This change eliminates future rent obligations for the remaining lease term but incurs an immediate cash outflow for the termination fee.
Guidance, Outlook, and Risks
Management Commentary and Context: The lease termination is linked to a pending merger with Ocugen, Inc., as evidenced by the reference to the "Agreement and Plan of Merger and Reorganization" dated April 5, 2019. The contingent payment clause is directly tied to the financial outcome of this merger.
Risks and Contingencies:
- Contingent Liability: The company faces a potential additional liability of $315,795 depending on the cash adjustment amount in the merger.
- Waiver of Rights: The company waived rights to tax abatement proceeds, operation expense adjustments, and utility charge adjustments through the termination date.
Important Facts for Investor Verification
- Verify the status of the merger between Histogenics Corporation and Ocugen, Inc., as the contingent payment depends on the "Parent Cash Adjustment Amount."
- Confirm the immediate cash impact of the $1,342,102.93 termination payment on the company's liquidity.
- Review the original lease terms to understand the total rent savings achieved by terminating the lease five years early.
- Check subsequent filings to determine if the contingent payment of $315,795 was triggered and paid.